Skip To Main Content
Angelica Barone on Muck Rack

Angelica Barone

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Angelica

Contact Angelica, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes

|
By Chiara De Philippis, Federico Stella, Anna Dodero, Angelica Barone
| Wiley Online Library Verified
INTRODUCTION Anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy has changed the treatment paradigm for relapsed or refractory (R/R) large B-cell lymphomas (LBCL) with durable remission rates in 30%–40% of patients both in pivotal and real-life studies.1-5 However, approximately 60% of the patients eventually relapse,6, 7 facing a poor prognosis with a median overall survival (OS) of only 8 months.8, 9 CD3xCD20 bispecific antibodies (BsAb) have demonstrated impressive efficacy in R/R...
Open in Who Shared Issue with article?
See all 1 articles